Unravelling the benefit against the risk of long-term dual antiplatelet therapy

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Dual antiplatelet therapy (DAPT) is crucial for managing acute coronary syndromes (ACS) and after percutaneous coronary intervention (PCI).
• The optimal duration of DAPT remains a significant clinical question.
• Existing studies have limitations in definitively establishing long-term benefits and risks.

Purpose of the Study:

• To evaluate the effectiveness and safety of long-term antiplatelet therapy.
• To assess the duration of dual antiplatelet therapy (DAPT) in preventing cardiovascular events.
• To analyze the risk-benefit profile of extended DAPT regimens.

Main Methods:

• Review of key studies, including Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) and PCI-CURE.
• Analysis of efficacy and safety data for DAPT in ACS and post-PCI settings.
• Evaluation of newer antiplatelet agents like prasugrel and ticagrelor.

Main Results:

• DAPT beyond one month shows benefit in preventing ischemic events post-ACS or post-PCI.
• The precise long-term benefit of DAPT after PCI, independent of pretreatment, is undetermined.
• Long-term DAPT significantly increases the risk of major bleeding complications.
• The net clinical effect of aspirin monotherapy in the current era is unknown.
• Newer agents like prasugrel and ticagrelor demonstrated favorable profiles in trials.

Conclusions:

• Despite extensive research, the definitive efficacy of long-term dual antiplatelet therapy (DAPT) is not yet established.
• Further research is needed to clarify the optimal duration and net clinical benefit of DAPT.
• Balancing ischemic event prevention against bleeding risk remains a critical challenge in DAPT management.